Latest news
Business Update
Innosuisse-Funded Alzheimer’s Clinical Trial with MIAMIND®
The MIAMIND® electrical neurostimulator will be evaluated in a randomized, sham-controlled clinical trial in patients with early-stage Alzheimer’s disease (AD), supported by funding from Innosuisse.
08 April, 2026
Read more
Events & Conferences | Wed 10, 2025
Sachs Associates 12th Annual Healthtech Investment Forum
Bottneuro CSO, Alois Hopf, PhD, and Bottneuro AG Board Member Antonella Santuccione Chadha, MD, had a talk at the Sachs Associates 12th Annual Healtht
Business Update | Fri 05, 2025
Bottneuro Launches Miamind.ch
Bottneuro AG announces the launch of miamind.ch, the official online platform for the Miamind® Neurostimulator.
Publication | Thu 05, 2025
Bottneuro publishes it's first publication in NeuroImage
Our team’s first publication in NeuroImage presents a novel approach to personalized brain stimulation using 3D-printed caps with flexible electrode p
Business Update | Wed 12, 2024
Kopfwehzentrum Hirslanden joins Priority Access Program
We are happy to welcome the Kopfwehzentrum Hirslanden as an early adopter of our Priority Access Program for migraine patients!
Featured news
Bottneuro Team
Dr Antonella Santuccione Chadha joins the Board of Directors at Bottneuro
02 June, 2025
